Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Demographic and clinical baseline characteristics of study participants

From: Limited restoration of T cell subset distribution and immune function in older people living with HIV-1 receiving HAART

  

HAART

Pre-HAART

 

Parameter

Overall (N = 146)

Adult (N = 38)

Middle (N = 15)

Old (N = 29)

Adult (N = 27)

Middle (N = 18)

Old (N = 19)

P

Age (years)

39.5 (28.0, 52.0)

28.0 (26.0, 30.0)

41.0 (39.0, 44.0)

58.0 (53.0, 65.0)

23.0 (21.0, 28.5)

43.5 (41.0, 48.0)

54.0 (51.0, 57.0)

< 0.0001

Gender (%)

       

0.339

Male

99 (67.8)

25 (65.8)

9 (60.0)

18 (62.1)

23 (85.2)

13 (72.2)

11 (57.9)

 

Female

47 (32.2)

13 (34.2)

6 (40.0)

11 (37.9)

4 (14.8)

5 (27.8)

8 (42.1)

 

Marriage (%)

      

< 0.001

Divorced or separated

21 (14.4)

0 (0.0)

2 (13.3)

5 (17.2)

1 (3.7)

5 (27.8)

8 (42.1)

 

Married or live togerther

48 (32.9)

3 (7.9)

5 (33.3)

24 (82.8)

1 (3.7)

7 (38.9)

8 (42.1)

 

Never married or single

71 (48.6)

35 (92.1)

8 (53.3)

0 (0.0)

24 (88.9)

3 (16.7)

1 (5.3)

 

Unclear

6 (4.1)

0 (0.0)

0 (0.0)

0 (0.0)

1 (3.7)

3 (16.7)

2 (10.5)

 

Infection route(%)

      

< 0.001

Homosexual

35 (24.0)

16 (42.1)

3 (20.0)

0 (0.0)

14 (51.9)

0 (0.0)

2 (10.5)

 

Heterosexual

85 (58.2)

21 (55.3)

6 (40.0)

22 (75.9)

11 (40.7)

11 (61.1)

14 (73.7)

 

Intravenous drug use.

9 (6.2)

0 (0.0)

2 (13.3)

4 (13.8)

0 (0.0)

3 (16.7)

0 (0.0)

 

Others/Unclear*

17 (11.6)

1 (2.6)

4 (26.7)

3 (10.3)

2 (7.4)

4 (22.2)

3 (15.8)

 

Initial HAART regimen (%)

      

0.654

NRTIs + NNRTIs

136 (93.2)

35 (92.1)

13 (86.7)

29 (100.0)

25 (92.6)

16 (88.9)

18 (94.7)

 

PIs

4 (2.7)

2 (5.3)

1 (6.7)

0 (0.0)

1 (3.7)

0 (0.0)

0 (0.0)

 

INSTIs

6 (4.1)

1 (2.6)

1 (6.7)

0 (0.0)

1 (3.7)

2 (11.1)

1 (5.3)

 

Current HAART regimen

      

0.052

NRTIs + NNRTIs

110 (75.3)

28 (73.7)

8 (53.3)

20 (69.0)

22 (81.5)

14 (77.8)

18 (94.7)

 

PIs

21 (14.4)

9 (23.7)

4 (26.7)

3 (10.3)

3 (11.1)

1 (5.6)

1 (5.3)

 

INSTIs

15 (10.3)

1 (2.6)

3 (20.0)

6 (20.7)

2 (7.4)

3 (16.7)

0 (0.0)

 

Anti-HBsAg

        

Negative

142 (97.3)

37 (97.4)

14 (93.3)

27 (93.1)

27 (100.0)

18 (100.0)

19 (100.0)

0.4728

Positive

4 (2.7)

1 (2.6)

1 (6.7)

2 (6.9)

0 (0.0)

0 (0.0)

0 (0.0)

 

Anti-HCV

        

Negative

137 (93.8)

38 (100.0)

13 (86.7)

25 (86.2)

27 (100.0)

16 (88.9)

18 (94.7)

0.0974

Positive

9 (6.2)

0 (0.0)

2 (13.3)

4 (13.8)

0 (0.0)

2 (11.1)

1 (5.3)

 

Anti -CMV#

        

Negative

123 (87.2)

33 (86.8)

10 (66.7)

25 (86.2)

22 (91.7)

17 (94.4)

16 (94.1)

0.1725

Positive

18 (12.8)

5 (13.2)

5 (33.3)

4 (13.8)

2 (8.3)

1 (5.6)

1 (5.9)

 

Anti -EBV#

        

Negative

119 (84.4)

33 (86.8)

10 (66.7)

25 (86.2)

22 (91.7)

14 (77.8)

15 (88.2)

0.3495

Positive

22 (15.6)

5 (13.2)

5 (33.3)

4 (13.8)

2 (8.3)

4 (22.2)

2 (11.8)

 

BMI

21.0 (19.4, 23.4)

20.0 (18.9, 21.2)

21.8 (18.9, 23.6)

21.2 (19.9, 23.2)

20.6 (18.8, 23.3)

23.4 (21.6, 24.3)

21.8 (19.8, 23.4)

0.0535

WBC (×109/L)

5.56 (4.35, 6.84)

5.6 (4.4, 7.3)

6.2 (5.5, 7.8)

5.1 (4.1, 6.3)

5.8 (4.9, 7.0)

5.8 (4.2, 6.4)

4.7 (3.8, 5.6)

0.1318

PLT (×109/L)

246.0 (199.0, 283.0)

255.5 (225.0, 277.8)

254.0 (222.0, 287.0)

195.0 (143.0, 249.0)

264.0 (213.0, 322.0)

246.0 (201.0, 292.0)

258.0 (191.0, 283.0)

0.0023

Hb (g/L)

155.0 (142.0, 173.0)

170.5 (146.5, 180.0)

151.0 (142.5, 157.5)

153.0 (137.0, 163.0)

160.0 (144.5, 172.4)

152.0 (108.0, 161.0)

146.0 (130.0, 157.0)

0.004

Cre (µmol/L)

69.0 (59.0, 78.0)

68.0 (58.2, 76.5)

67.0 (58.5, 74.5)

72.0 (61.0, 78.0)

71.0 (62.5, 77.8)

68.0 (65.0, 73.0)

62.0 (54.0, 83.0)

0.7362

TG (mmol/L)

1.6 (1.2, 2.2)

1.5 (1.2, 2.1)

2.0 (1.2, 3.1)

1.6 (1.1, 2.4)

1.4 (1.2, 1.9)

1.7 (1.2, 2.5)

1.9 (1.4, 2.0)

0.7203

CHO (mmol/L)

4.7 (4.2, 5.5)

4.8 (4.4, 5.4)

4.9 (4.3, 5.6)

5.1 (4.2, 6.1)

4.3 (3.9, 4.9)

5.0 (4.4, 5.4)

4.5 (4.2, 5.4)

0.1923

Glu (mmol/L)

5.4 (5.0, 5.8)

5.2 (4.9, 5.4)

5.3 (5.1, 5.7)

5.6 (5.2, 6.3)

5.3 (5.0, 5.8)

5.7 (5.4, 5.7)

6.0 (5.2, 6.6)

0.0025

ALT (U/L)

22.0 (15.5, 32.5)

20.0 (14.2, 33.8)

25.0 (19.0, 27.0)

23.0 (19.0, 30.0)

19.0 (14.0, 25.0)

25.0 (20.0, 39.0)

28.0 (13.0, 31.0)

0.4659

AST (U/L)

22.0 (18.0, 27.0)

21.0 (18.0, 25.0)

22.0 (20.0, 25.0)

24.0 (19.0, 32.0)

18.0 (16.0, 21.5)

26.0 (20.0, 31.0)

25.0 (18.0, 32.0)

0.0191

TBIL (µmol/L)

9.0 (6.7, 12.1)

8.9 (6.7, 12.5)

9.0 (7.2, 14.7)

10.4 (8.6, 13.5)

10.1 (7.2, 12.2)

7.2 (6.1, 9.9)

6.7 (5.6, 8.6)

0.0255

b.CD4+T (cells /µL)&

285 (175, 419)

325 (251, 455)

202 (85, 282)

200 (97, 314)

380 (262, 524)

227 (166, 312)

260 (129, 448)

< 0.001

b.CD8+T (cells /µL)&

1041 (745, 1514)

860 (713, 1502)

820 (490, 1537)

833 (594, 1175)

1448 (1163, 1730)

1092 (843, 1359)

1082 (803, 1593)

0.014

b.CD4/CD8&

0.22 (0.14, 0.43)

0.37 (0.21, 0.49)

0.20 (0.09, 0.23)

0.16 (0.13, 0.36)

0.28 (0.18, 0.45)

0.17 (0.14, 0.23)

0.22 (0.14, 0.38)

0.023

  1. Figures are n (%) or median (IQR). *Others/Unclear included blood transfusion, mother to child transmission, and unknown. #Due to unavailability of plasma samples, 5 PLWH had to be excluded for the CMV and EBV screen. &b.Representation of the baseline. HAART: Highly active antiretroviral treatment, NRTIs: nucleoside reverse transcriptase inhibitors, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, INSTI: integrase strand transfer inhibitor, WBC: white blood cell count, PLT: platelet, Hb: hemoglobin, Cre: creatinine, CHO: cholesterol, TG: triglycerides, Glu: blood glucose, ALT: alanine transaminase, AST: aspartate transaminase, TBIL: total bilirubin, Anti-BsAg: hepatitis B surface antigen, Anti-HCV: antibodies against the hepatitis C virus, Anti-CMV: antibodies against cytomegalovirus; Anti-EBV: antibodies against cytomegalovirus
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us